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Abstract
Background: In the literature we find many indices of size of treatment effect (effect size: ES). The preferred index of
treatment effect in evidence-based medicine is the number needed to treat (NNT), while the most common one in the
medical literature is Cohen’s d when the outcome is continuous. There is confusion about how to convert Cohen’s d into
NNT.
Methods: We conducted meta-analyses of individual patient data from 10 randomized controlled trials of second
generation antipsychotics for schizophrenia (n=4278) to produce Cohen’s d and NNTs for various definitions of response,
using cutoffs of 10% through 90% reduction on the symptom severity scale. These actual NNTs were compared with NNTs
calculated from Cohen’s d according to two proposed methods in the literature (Kraemer, et al., Biological Psychiatry, 2006;
Furukawa, Lancet, 1999).
Results: NNTs from Kraemer’s method overlapped with the actual NNTs in 56%, while those based on Furukawa’s method
fell within the observed ranges of NNTs in 97% of the examined instances. For various definitions of response corresponding
with 10% through 70% symptom reduction where we observed a non-small number of responders, the degree of
agreement for the former method was at a chance level (ANOVA ICC of 0.12, p=0.22) but that for the latter method was
ANOVA ICC of 0.86 (95%CI: 0.55 to 0.95, p,0.01).
Conclusions: Furukawa’s method allows more accurate prediction of NNTs from Cohen’s d. Kraemer’s method gives a
wrong impression that NNT is constant for a given d even when the event rate differs.
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Introduction
When a clinician and a patient jointly decide on a treatment,
they need to know how much the treatment in question is better
than an alternative treatment and in what respect. Effect size (ES)
is an index, a single number preferably, that expresses this HOW
MUCH.
Clinical decision-making is facilitated by consideration of the
difference in risk of important beneficial (e.g. remission of an
episode) or adverse (e.g. suicide) events or the reciprocal of this risk
difference, the number needed to treat (NNT) [1,2,3]. The NNT is
defined as the number of patients one would need to treat with the
intervention in question in order to have one more success (or one
less failure) than if treated in the control intervention. It is
calculated by the following formula:
NNT~
1
EER{CER
where EER is the experimental event rate and CER is the control
event rate. For example, if the response rate in the acute phase
treatment of a major depressive episode is 60% in the active drug
arm (EER) and 30% in the placebo arm (CER), the NNT will be
calculated as 1/(0.620.3)=3.3. In order to simplify the argument,
here and in the following, we assume that an intervention aims at
increasing the event rate, so that EER is greater than CER. When
an intervention is a preventative one, we need to exchange EER
and CER appropriately.
When the outcome is continuous, however, the most common
summary ES index in the medical literature is Cohen’s d [4].
Clinicians and patients may find it challenging to understand the
magnitude of effect in terms of Cohen’s d, and so it is deirable to
express results as a risk difference or NNT but conversion from
Cohen’s d to NNT is not self-evident. One of the authors has once
proposed a conversion table from Cohen’s d to NNT, under the
assumption of normal distributions and equal variances in the
intervention and control groups [5]. In this approach NNT is
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scale. Using the CER that corresponds with this threshold,
NNT~
1
W d{Y CER ðÞ ðÞ {CER
where W is the cumulative distribution function of the standard
normal distribution and Y is its inverse. This formula shows that,
given a certain Cohen’s d, NNT will differ according to the
response threshold you expect and the CER associated with that
threshold.
Recently Kraemer and Kupfer [6] reviewed the commonly used
ES indices and, based on the principles of statistical significance
and power, recommended area under the receiver operating
characteristics (AUC) comparing treatment and control responses,
success rate difference (SRD), and number needed to treat (NNT).
AUC is defined as the probability that a patient in the treatment
has an outcome preferable to one in the control, and SRD as the
difference between the probability that a patient in the treatment
has an outcome preferable to one in the control and the
probability that a patient in the control has an outcome preferable
to one in the treatment. Thus,
SRD~AUC{ 1{AUC ðÞ ~2|AUC{1
They further demonstrated that, when Cohen’s d is appropriate
(normal distributions, equal variances), it can be converted into
AUC by the formula:
AUC~W
d
ﬃﬃﬃ
2
p
  
Therefore,
SRD~2|W
d
ﬃﬃﬃ
2
p
  
{1
NNT is then calculated as:
NNT~
1
2|W
d
ﬃﬃﬃ
2
p
  
{1
This NNT can therefore be interpreted as the number of patients one
would need to treat with the intervention in order to have one more
patient to have an outcome better than a randomly selected one in
the control group than if the samenumber had been given the control
intervention. This definition is clinically abstract and beyond
comprehension of even well-informed clinicians and patients.
However, it has been used in several recent important meta-analyses
to quantify the obtained effect size [7,8,9]. As can be easily seen from
the formula, this NNT is constant, given a certain Cohen’s d.
Furukawa’s method and Kraemer’s method to convert Cohen’s
d into NNT are therefore at odds with each other. This paper aims
to empirically examine and compare these two approaches, based
on the individual patient data of randomized controlled trials of
second generation antipsychotics in the acute phase treatment of
patients with schizophrenia.
Methods
Database
Individual patient data from 10 trials comparing olanzapine vs
placebo (2 comparisons, baseline n=502) [10,11], olanzapine vs
haloperidol (5 comparisons, baseline n=2974) [10,12,13,14,15],
and amisulpride vs haloperidol (4 comparisons, baseline n=1198)
[16,17,18,19] in the acute phase treatment of schizophrenia that
administered either the BPRS or PANSS were reanalyzed post hoc.
One trial was a three-armed trial among olanzapine, haloperidol
and placebo, and contributed to two comparisons. Important
characteristics of the included studies are presented in Table 1.
All studies were randomized and all but one [17] were described
as double-blind. All amisulpride studies and one olanzapine study
[10] used the original BPRS, and all the other olanzapine studies
used PANSS. For the latter studies we calculated the PANSS-
derived BPRS scores because PANSS includes all items of the
BPRS.
For fixed-dose studies, we selected only those arms with
optimum doses of second-generation antipsychotic drugs as
reported in dose-finding studies (amisulpride 400–800 mg/day,
olanzapine 10–20 mg/day and risperidone 4–6 mg/day) [20]. We
therefore excluded 61 participants from Puech et al (1998) [19]
who had received a potentially subtherapeutic 100 mg/day of
amisulpride, 175 participants from Beasley et al (1997) [12] who
received 5 mg/day or 1 mg/day of olanzapine, 65 participants
from Beasley et al 1996 [10] who were given 5 mg/day of
olanzapine and 52 participants from Beasley et al 1996 [11] who
received 1 mg/day of olanzapine.
The mean BPRS total score of the included participants was
54.3 (SD=10.8) at baseline. There were 2895 men and 1383
women. Their mean age was 36.6 (10.5) years, weight 75.5 (16.4)
kg and height 171.6 (9.6) cm.
Statistical analyses
We first conducted meta-analyses of the BPRS or PANSS total
score at 4 weeks for the three comparisons of olanzapine vs
haloperidol, amisulpride vs haloperidol and olanzapine vs placebo,
using Review Manager software by the Cochrane Collaboration
[21]. 4-week was chosen because all the studies reported BPRS at
this point in time. Following the strict intention-to-treat principle,
missing data were supplemented by the last-observation-carried-
forward (LOCF) method even when a participant dropped out
before the first post-baseline rating. Unless statistically significant
heterogeneity was noted, we obtained the standardized mean
difference (Cohen’s d) based on the Mantel-Haenszel fixed effect
model.
We next calculated the numbers of responders defined as 10%
through 90% reduction on the BPRS or PANSS total score at 4
weeks. The percentage reduction was calculated according to the
formulae: B%=(B02B4LOCF) * 100/(B0218) for BPRS and
P%=(P02P4LOCF) * 100/(P0230) for PANSS, where B0 and P0
are BPRS and PANSS scores at baseline and B4 and P4 are
respective scores at 4 weeks, because 18 and 30 are the minimum
scores for BPRS and PANSS, respectively, according to the
original rating system. We then ran meta-analyses of response
rates defined as 10% through 90% reduction for each comparison
in terms of risk difference. The pooled NNT was obtained by
taking the inverse of this pooled risk difference, because the
response rates for a certain cutoff did not differ substantively
among the trials included in the meta-analysis, [22].
These actual NNTs were then compared with NNTs converted
from Cohen’s d according to Kraemer’s method and to
Furukawa’s method using the formulae discussed in the Introduc-
tion. The agreement between the actual and the converted was
quantified by ANOVA intraclass correlation coefficient (two-way
mixed effects, absolute agreement, single measure) by using SPSS
Version 17.
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No statistical heterogeneity was observed for any of the meta-
analytic summaries. Table 2 tabulates the observed NNTs, NNTs
converted from Cohen’s d according to Kraemer’s method and
those according to Furukawa’s method for the three comparisons
of olanzapine vs haloperidol, amisulpride vs haloperidol and
olanzapine vs placebo on BPRS and for the comparison of
olanzapine vs haloperidol on PANSS. All but one of the estimated
NNTs according to Furukawa’s method were included in the 95%
confidence intervals of the observed NNTs (35 out of 36, 97%),
whereas those calculated by Kraemer’s method were within those
ranges in 20 out of 36 (56%) instances only. It should also be noted
that Kraemer’s NNTs were almost always smaller than (i.e.
overestimates of) the actual NNTs.
The ANOVA ICC of absolute agreement between the actual
NNT and those estimated by Kraemer’s method was 0.06 (20.34
to 0.43, p=0.39) and that for Furukawa’s method was 0.33 (20.01
to 0.62, p=0.03). When the response is defined at thresholds as
high as 80% or 90% reduction, the CER becomes extremely low
and the NNT may be considered degenerate with negative
numbers and with 95% confidence intervals extending to infinity.
We therefore calculated the ANOVA ICC for the ranges from
10% through 70% reduction where we observed relatively
constant OR for these different definitions of response [23]. The
ANOVA ICC was 0.12 (20.16 to 0.45, p=0.22) for Kraemer’s
method but 0.86 (0.55 to 0.95, p,0.01) for Furukawa’s method.
Discussion
Each meta-analysis comparing olanzapine vs placebo, olanza-
pine vs haloperidol, and amisulpride vs haloperidol produces a
single Cohen’s d. This single effect size was converted into NNTs
according to Kraemer’s method and Furukawa’s method, and
compared with the actual NNTs using various cutoffs to define
response. NNTs from Kraemer’s method overlapped with the
observed NNT in 56% of the examined instances but the degree of
agreement was at a chance level (ANOVA ICC of 0.12, p=0.22 at
best). Those based on Furukawa’s method fell within the observed
plausible ranges of NNTs in 97% of the instances and the degree
of agreement was ANOVA ICC of 0.86 (0.55 to 0.95, p,0.01) for
various definitions of response corresponding with 10% through
70% reduction on the rating scale where we expect to observe a
non-small number of responders.
The reason for this difference in performance is that the latter
method takes into account the fact that, for a given d on a
continuous outcome measure, the response rate can vary
depending on the cutoff one adopts to define response. This
individualized consideration in assessing clinical importance of
Cohen’s d is extremely important. For example, d of olanzapine
over haloperidol in the acute phase treatment of schizophrenia is
approximately 0.17. On the other hand, olanzapine causes more
significant weight gain than haloperidol, with an NNH estimated
to be around 6 (95%CI: 4–11) [24]. A patient who is normo- to
underweight now and who does not have any family and other risk
factors for obesity may be happy to try olanzapine to achieve a
30% or more decrease in disease severity. For this patient, given
an estimate that 40% of the patients would achieve 30% or more
reduction on BPRS when given haloperidol (Cf. Table 2), NNT
will be calculated to be 15, and he or she may find this NNT small
enough in comparison with NNH for weight gain to justify
treatment with olanzapine. On the other hand, another patient
who is already somewhat overweight and has multiple family
history of diabetes mellitus and cardiovascular diseases may like
70% or more decrease in the BPRS before he/she selects
olanzapine over haloperidol. However, because the control event
rate for 70% reduction could be as low as 6% and the
corresponding NNT may be as large as 43, he/she might reason
that trying olanzapine may not be worthwhile.
Table 1. Characteristics of the included studies.
Study Antipsychotic drugs and daily dosage (mg) Sample size (n) Mean BPRS at baseline
Beasley et al 1996 [11] Olanzapine 10
Placebo
50
50
55.2
Beasley et al 1996 [10] Olanzapine 10–15
Haloperidol 15
Placebo
133
69
68
59.9
Beasley et al 1997 [12] Olanzapine 10–15
Haloperidol 15
175
81
59.1
Tollefson et al 1997 [15] Olanzapine 5–20
Haloperidol 5–20
1337
659
51.5
Lieberman et al 2003 [14] Olanzapine 5–20
Haloperidol 2–20
131
132
46.8
Keefe et al 2006 [13] Olanzapine 5–20
Haloperidol 2–19
159
97
48.4
Mo ¨ller et al 1997 [18] Amisulpride 600–800
Haloperidol 15–20
95
96
61.7
Puech et al 1998 [19] Amisulpride 400–1200
Haloperidol 16
194
64
61.3
Colonna et al 2000 [17] Amisulpride 200–800
Haloperidol 5–20
368
118
56.2
Carrie `re et al 2000 [16] Amisulpride 400–1200
Haloperidol 10–30
97
105
65.4
BPRS: Brief Psychiatric Rating Scale, CGI-S: Clinical Global Impression Severity Scale, DSM: Diagnostic and Statistical Manual of Mental Disorders, PANSS: Positive and
Negative Syndrome Scale.
doi:10.1371/journal.pone.0019070.t001
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according to Furukawa’s method for various definitions of response.
Olanzapine vs placebo (BPRS), d=0.34
Definition of response CER Actual NNT Kraemer’s method Furukawa’s method
10% 0.42 5.9 (3.4 to 20) 5.3 7.4
20% 0.35 7.1 (4.0 to 50) 5.3 7.6
30% 0.26 6.7 (4.0 to 25) 5.3 8.3
40% 0.21 9.1 (4.5 to 100) 5.3 9.1
50% 0.16 11.1 (5.3 to ‘) 5.3 10.4
60% 0.11 16.7 (2‘ to 250, 7.7 to ‘) 5.3 12.9
70% 0.06 25.0 (2‘ to 250, 9.1 to ‘) 5.3 19.1
80% 0.04 2100 (2‘ to 217, 25 to ‘) 5.3 25.5
90% 0.01 2100 (2‘ to 225, 50 to ‘) 5.3 74.1
Olanzapine vs haloperidol (BPRS), d=0.17
Definition of response CER Actual NNT (95%CI) Kraemer’s method Furukawa’s method
10% 0.64 12.5 (9.1 to 25) 10.5 16.3
20% 0.52 11.1 (7.7 to 16.7) 10.5 14.9
30% 0.40 11.1 (7.7 to 16.7) 10.5 15.0
40% 0.29 12.5 (9.1 to 25) 10.5 16.5
50% 0.19 14.3 (10 to 25) 10.5 20.2
60% 0.11 25.0 (14.3 to 50) 10.5 28.3
70% 0.06 33.3 (20 to 100) 10.5 43.4
80% 0.02 33.3 (25 to 100) 10.5 102.0
90% 0.005 100 (50 to ‘) 10.5 326.0
Olanzapine vs haloperidol (PANSS), d=0.17
Definition of response CER Actual NNT Kraemer’s method Furukawa’s method
10% 0.61 12.5 (8.3 to 25) 10.5 15.8
20% 0.47 11.1 (7.7 to 20) 10.5 14.8
30% 0.34 11.1 (7.7 to 20) 10.5 15.6
40% 0.23 14.3 (10 to 25) 10.5 18.2
50% 0.15 20.0 (14.3 to 50) 10.5 23.2
60% 0.09 33.3 (20 to 100) 10.5 33.6
70% 0.04 58.8 (28 to 200) 10.5 62.4
80% 0.01 47.6 (31 to 100) 10.5 162.7
90% 0.004 125 (71 to ‘) 10.5 384.5
Amisulpride vs haloperidol (BPRS), d=0.21
Definition of response CER Actual NNT Kraemer’s method Furukawa’s method
10% 0.78 16.7 (9.1 to 100) 8.5 17.5
20% 0.67 10.0 (6.3 to 20) 8.5 13.9
30% 0.57 9.1 (5.9 to 20) 8.5 12.4
40% 0.49 10.0 (5.9 to 25) 8.5 12.0
50% 0.38 7.7 (5.3 to 14.3) 8.5 12.2
60% 0.26 9.1 (5.9 to 20) 8.5 13.8
70% 0.17 14.3 (8.3 to 50) 8.5 17.1
80% 0.09 25.0 (12.5 to ‘) 8.5 25.6
90% 0.02 33.3 (20 to 100) 8.5 79.3
BPRS: Brief Psychiatric Rating Scale, PANSS: Positive and Negative Syndrome Scale.
doi:10.1371/journal.pone.0019070.t002
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argue at the population level. For example, Cohen’s d of 0.2 is
usually regarded as small effect [25]. However, it corresponds with
an NNT of 17 for an event that can happen in 2 out of 10 patients
when given the control treatment. ‘‘Remission’’ by an antidepres-
sant treatment is an event that happens at this frequency. In Japan,
for example, it is estimated that currently around two million
people are receiving antidepressant treatment annually. If we can
find a new treatment that is better than the current treatment as
usual by Cohen’s d of 0.2, it can bring about remission in
additional 100 thousand or more people that would not have done
so on the current treatment. This of course is no trivial number.
One possible drawback of Furukawa’s method is that it requires
estimation of control event rate in order to predict NNTs
accurately. However we argue that this is more of a strength than
a weakness of this method, because this is what EBM practitioners
normally do when they apply group-level evidence to individuals
[26]. In this connection we would like to emphasize that in the
original report of a clinical trial it will be more informative not
only to report the overall ES but also the control event rates for
different definitions of response in a tabular format [27].
Conversely one can argue that the reason why Kraemer’s
method turned out to be less efficient is because they subtly re-
defined NNT for a continuous outcome as the inverse of the
difference between the probability that a patient in the treatment
has an outcome preferable to one in the control and the
probability that a patient in the control has an outcome preferable
to one in the treatment. This definition is slightly different from the
conventional definition of NNT in EBM [28].
The interpretation of a quantified effect size is inherently
difficult and variable [29,30], and this is precisely the reason why
we have to quantify instead of qualifying. Kraemer’s method has
been used in several recent meta-analyses to quantify the obtained
effect size [7,8,9]. Furukawa’s method has been cited in the
Cochrane Handbook as a way to re-express Cohen’s d in terms of
NNT [31]. Given the present results, a greater precaution is called
for in converting the obtained Cohen’s d into one single NNT
value according to Kraemer’s method. After all, how best to apply
group evidence to meet individual patients’ needs and values is the
defining essence of EBM, and NNT is a means to this end, we
therefore had better take individual patients’ differences, including
their expected event rates, into consideration when we present
NNTs to them.
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